Ivermectin affects energy metabolism for its anticancer efficiency through targeting PFKP, IDH2, IDH3B, ND2, ND5, CYTB, UQCRH, MCT1, and MCT4 at the protein levels analyzed with western blot. EOC cells adding ivermectin (10 μM, 20 μM, and 30 μM) and control cell lines (within 0.1% DMSO) were verified by western blot to detect the protein expression of FPKP, PKM, PDHB,CS, IDH2, IDH3A, IDH3B, OGDHL, ND2, ND5, CYTB, UQCRH, MCT1, and MCT4 (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001. PFK, phosphofructokinase platelet; IDH2, isocitrate dehydrogenase (NADP(+)) 2, IDH3A, mitochondrial isocitrate dehydrogenase [NAD] subunit alpha; IDH3B, isocitrate dehydrogenase (NAD(+)) 3 noncatalytic subunit beta; ND2, mitochondrially encoded NADH dehydrogenase 2; ND5, mitochondrially encoded NADH dehydrogenase 5; UQCRH:, ubiquinol-cytochrome c reductase hinge protein; MCT1, solute carrier family 16 member 1; MCT4, solute carrier family 16 member 4; EOC, epithelial ovarian carcinoma; CYTB, mitochondrially encoded cytochrome b; DMSO, dimethyl sulfoxide; PKM, pyruvate kinase muscle; PDHB, pyruvate dehydrogenase E1 subunit beta; CS, citrate synthase; OGDHL, oxoglutarate dehydrogenase L